Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06442761 · ClinicalTrials.gov registry record · Phase 1

SCD Stem Cell Mobilization and Apheresis Using Motixafortide

A Phase 1 study of Sickle Cell Disease, sponsored by St. Jude Children's Research Hospital.

Recruiting
Registry status
Phase 1
Development phase
15
Enrollment target
2
Study locations

NCT06442761 is a Phase 1 study of Sickle Cell Disease that is actively recruiting participants, run by St. Jude Children's Research Hospital. The registered enrollment target is 15 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06442761, a Phase 1 study of Sickle Cell Disease, is actively recruiting participants, sponsored by St. Jude Children's Research Hospital.

RECRUITING
Registry status
Phase 1
Development phase
15 participants
Enrollment target
2
Study locations

Study Summary

This study is being done to see if the study drug, motixafortide, is safe in participants with sickle cell disease (SCD). Investigators also want to see if the drug will help the body increase the number of stem cells that can be collected for possible future transplant use. PRIMARY OBJECTIVE * To characterize the safety and tolerability of motixafortide in participants with SCD as determined by the incidence of adverse events (AEs). SECONDARY OBJECTIVES * To characterize the efficacy of a single dose (Part A) or two doses (Part B) of motixafortide for hematopoietic stem cell (HSC) mobilization and apheresis collection in participants with SCD as determined by the yield of CD34+ cells (CD34+ cells/kg). * To measure the mobilization effects of single-day (Part A) or daily dosing (Part B) dosing with motixafortide in the peripheral blood in participants with SCD as determined by peak peripheral blood CD34+ counts * To recommend a phase 2 dosing strategy based on safety, efficacy, and mobilization effects

Conditions Studied

Sickle Cell Disease

Interventions

  • DRUG Motixafortide

Study Locations (2)

Alabama

  • University of Alabama at Birmingham - Birmingham

Tennessee

  • St. Jude Children's Research Hospital - Memphis

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2024-11-14
Est. Completion 2028-07
Phase Phase 1

Sponsor

St. Jude Children's Research Hospital

410 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06442761

The ClinicalTrials.gov registry entry for NCT06442761 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (95% lower). The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 1 intervention - of which Motixafortide is the first listed.

NCT06442761 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Alabama, Tennessee.

Frequently Asked Questions

What is clinical trial NCT06442761 about?

NCT06442761 is a clinical study titled "SCD Stem Cell Mobilization and Apheresis Using Motixafortide". This study is being done to see if the study drug, motixafortide, is safe in participants with sickle cell disease (SCD). Investigators also want to see if the drug will help the body increase the number of stem cells that can be collected for possible future transplant use. PRIMARY OBJECTIVE * To...

What is the current status of trial NCT06442761?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2024-11-14. Estimated completion is 2028-07.

What conditions does trial NCT06442761 study?

This clinical trial studies the following conditions: Sickle Cell Disease.

What interventions are being tested in trial NCT06442761?

The interventions under investigation include: Motixafortide (DRUG).

Who is sponsoring clinical trial NCT06442761?

This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06442761 being conducted?

This trial has 2 study locations across Alabama, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Sickle Cell Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Sickle Cell Disease

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.